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Abstract
Pancreatic neoplasms producing exclusively glucagon 
associated with glucagon cell hyperplasia of the islets 
and not related to hereditary endocrine syndromes have 
been recently described. They represent a novel entity 
within the panel of non-syndromic disorders associated 
with hyperglucagonemia. This case report describes 
a 36-year-old female with a 10 years history of non-
specific abdominal pain. No underlying cause was evident 
despite extensive diagnostic work-up. More recently 
she was diagnosed with gall bladder stones. Abdominal 
ultrasound, computerised tomography and magnetic 
resonance imaging revealed no pathologic findings apart 
from cholelithiasis. Endoscopic ultrasound revealed a 5.5 
mm pancreatic lesion. Fine needle aspiration showed 
cells focally expressing chromogranin, suggestive but 
not diagnostic of a low grade neuroendocrine tumor. 
OctreoScan® was negative. Serum glucagon was elevated 
to 66 pmol/L (normal: 0-50 pmol/L). Other gut hormones, 
chromogranin A and chromogranin B were normal. 
Cholecystectomy and enucleation of the pancreatic lesion 
were undertaken. Postoperatively, abdominal symptoms 
resolved and serum glucagon dropped to 7 pmol/L. 
Although H and E staining confirmed normal pancreatic 
tissue, immunohistochemistry was initially thought to be 
suggestive of alpha cell hyperplasia. A count of glucagon 
positive cells from 5 islets, compared to 5 islets from 5 
normal pancreata indicated that islet size and glucagon 
cell ratios were increased, however still within the wide 
range of normal physiological findings. Glucagon receptor 
gene (GCGR) sequencing revealed a heterozygous deletion, 
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K349_G359del and 4 missense mutations. This case may 
potentially represent a progenitor stage of glucagon cell 
adenomatosis with hyperglucagonemia in the absence 
of glucagonoma syndrome. The identification of novel 
GCGR mutations suggests that these may represent the 
underlying cause of this condition.
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Core tip: We identify novel mutations in the glucagon 
receptor gene in a patient with hyperglucagonemia but 
no glucagonoma syndrome. Physicians dealing with 
pancreatic disorders should be aware of this unusual 
condition.
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INTRODUCTION
Glucagon cell adenomatosis has been reported by 
Henopp et al[1] as an independent previously un­
recognised disease of the endocrine pancreas. Multiple 
pancreatic neoplasms exclusively producing glucagon, 
associated with glucagon cell hyperplasia of the islets 
and unrelated to multiple endocrine neoplasia (MEN) 
type 1 (MEN 1), p27 MEN or von Hippel­Lindau (VHL) 
syndromes, are the hallmarks of the condition[2]. To 
date very few such patients have been reported[1,3,4].
Most patients present with abdominal pain and 
increased serum glucagon levels but fail to exhibit the 
characteristics of the glucagonoma syndrome (necrolytic 
migratory erythema, diabetes mellitus, stomatitis 
and weight loss)[5]. While macroscopic tumors are 
evident on imaging in some, numerous microadenomas 
scattered throughout the pancreas and enlarged islets 
are the findings in others[1,3,4]. Malignancy has not been 
identified in any cases reported to date. The underlying 
cause of glucagon cell hyperplasia and consequent 
development of glucagon cell neoplasia without the 
glucagonoma syndrome remains unknown. Yu et 
al[3], Zhou et al[6] have proposed that malfunction of 
the glucagon receptor (GCGR) and/or glucagon may 
be responsible for the disease after detection of a 
homozygous missense mutation, c.256C>T (P86S) in 
the GCGR of a patient.
We present another example of hyperglucagonemia 
without morphological evidence of neoplasia or the 
glucagonoma syndrome in which we identified GCGR 
mutations which may represent the underlying 
pathogenic cause of the condition.
CASE REPORT
A 36 years old Caucasian female with no previous 
medical or known family history was referred to us 
in 2011 with a 10 year history of non­specific diffuse 
abdominal pain. She repeatedly underwent complete 
gastrointestinal diagnostic work­up over a period 
of 8 years which revealed no pathologic results. In 
2009, she had been diagnosed with cholelithiasis on 
abdominal ultrasound. Upon referral to our centre in 
2011, extensive investigations including upper and 
lower intestinal endoscopy, computerised tomography 
and magnetic resonance imaging (MRI) were carried 
out. Apart from the previously diagnosed cholelithiasis, 
no other pathology was evident. Endoscopic ultrasound 
(EUS) confirmed calculi in the gallbladder and a mild 
dilatation of the distal common bile duct. In addition, a 
5.5 mm hypoechoic lesion with irregular margins was 
detected in the pancreatic tail. Fine needle aspiration 
(FNA) revealed cells focally expressing chromogranin 
A. The features were suggestive but not diagnostic of a 
low grade neuroendocrine tumor. Somatostatin receptor 
scintigraphy showed no foci of increased uptake. 
While serum gastrin, vasoactive intestinal polypeptide, 
somatostatin, and pancreatic polypeptide were within 
the normal range, glucagon was elevated to 66 pmol/L 
(normal: 0­50 pmol/L). Serum fasting and postprandial 
glucose was normal. Neuroendocrine tumor markers 
chromogranin A and chromogranin B were not elevated. 
At laparotomy, a sub­centimeter lobulated lesion 
was found at the inferior margin of the pancreatic 
tail corresponding with the lesion identified on EUS. 
No further lesions were identified in the remaining 
pancreas after meticulous bimanual exploration and 
intraoperative ultrasound. There were no enlarged 
peripancreatic lymph nodes. The pancreatic tail lesion 
was enucleated and cholecystectomy performed. A 
grade 1 pancreatic fistula developed postoperatively and 
resolved within 2 wk. The further course was uneventful 
and the patient was entirely asymptomatic. Moreover, 
she reported that the abdominal pain she experienced 
over the last decade had completely disappeared. 
Serum glucagon was assessed 1 mo postoperatively 
after the pancreatic morphology returned to normal on 
imaging. It was found to have decreased to 7 pmol/L. 
Serum glucagon was monitored at regular intervals 
(see Table 1). At the last follow­up, 31 mo after surgery, 
the patient remained asymptomatic with a normal MRI 
result, serum glucagon was 10 pmol/L and insulin was 
within the normal range. 
Histology (H and E) showed features of normal 
pancreatic tissue. Immunohistochemical examination 
for glucagon and insulin was undertaken using the 
technique of Henopp et al[1]. Approximately 20% 
of the islet cells were glucagon positive and 80% 
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control sample and the national centre for biotechnology 
information (NCBI) reference sequences for the human 
GCGR, DNA (NG_016409.1), mRNA (NM_000160.3) and 
protein (NP_000151.1).
MEN1 sequencing was carried out on gDNA from 
the peripheral blood. PCR amplification of exons 2­10 
of MEN1 was undertaken using previously described 
primers[9,10]. The DNA extraction, sequencing and 
analysis were carried out using the same technique 
as for GCGR. The reference sequence used was NCBI 
GenBank: U93237.1.
VHL sequencing was carried out on gDNA from the 
peripheral blood. PCR amplification of exons 1-3 of VHL 
was undertaken using primers previously described[11]. 
The DNA extraction, sequencing and analysis were 
carried out using the same technique as for GCGR. 
The reference sequence used was NCBI GenBank: 
NM_000551.3.
Results of genetic analysis
A heterozygous deletion of 33 nucleotides in exon 
11 of the GCGR was detected. This corresponded to 
a K349_G359del in the GCGR with the loss of the 
following 11 amino acids, KSTLTLIPLLG. There were 
also 5 heterozygous point mutations including 4 
missense mutations, E362K, V368L, K381E, S389N 
and 1 synonymous mutation (Figure 2). There were 
no mutations in MEN1 or VHL. No mutations were 
insulin positive. Glucagon cell hyperplasia was initially 
considered (Figure 1). In order to investigate this 
further, glucagon cell counts were done with 5 islets 
from 5 normal pancreatic controls and compared to 5 
islets from the patient (Table 2). The counts showed 
that the average islet size and the average number of 
glucagon positive cells per islet were increased in the 
patient, however still within the wide range observed 
in normal pancreatic tissue.
Methods of genetic investigation
A peripheral blood sample was obtained from the 
patient, her daughter and a healthy individual as a 
normal control (informed consent obtained). Genomic 
DNA (gDNA) was extracted using the DNeasy Blood and 
Tissue Kit according to the protocol (Qiagen, catalogue 
number: 9506). Polymerase chain reaction (PCR) 
amplification of exons 2­13 (and most of exon 14) of 
GCGR and the intron:exon borders was carried out using 
previously described primers[6]. Purified PCR products 
were sequenced by the W.M. Keck Biotechnology 
Resource Laboratory at Yale University, New Haven, 
United States using an automated Applied Biosystems 
373A Stretch DNA sequencer (Perkin­Elmer, Norwalk, 
United States). PCR products were sequenced using 
forward primers. If ambiguous peaks were evident, the 
sequence was confirmed with the reverse primers[7]. 
Bioedit software was used to analyse the sequencing 
results[8]. Sequencing products were compared to the 
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Figure 1  Islet from patient. Immunohistochemistry for A: Insulin; B: Glucagon, x 200 magnification (600 μm at maximum diameter).
Table 1  Serum glucagon levels
Time Serum glucagon (pmol/L) (normal range: 0-50 pmol/L)
Pre-surgery 
  2 mo 66
Post-surgery 
  1 mo 7
  5 mo 28
  6 mo 6
  17 mo 15
  20 mo 29
  31 mo 10
Table 2  Islet size and number of glucagon positive cells in 
the current case compared to 5 normal pancreata
Average1
islet size (μm)
Average1 number glucagon positive cells
Count 1 Count 2
Patient 192 29.2 28.8
Control 1 256 59.8 61.8
Control 2 186 25.6 25.2
Control 3 255 32.2 31.6
Control 4 260 52.4 53.4
Control 5 190 44.6 42.6
1Average of 5 pancreatic islets.
A B
detectable in the daughter.
DISCUSSION
This case report represents the second case of 
hyperglucagonemia which has been associated with 
a specific genetic lesion in the GCGR. The case could 
potentially represent a progenitor stage of an entity 
leading to glucagon cell adenomatosis. 
To date 8 individuals exhibiting characteristics of 
glucagon cell adenomatosis with hyperglucagonemia 
but without glucagonoma syndrome have been reported 
in the literature[1,3,4,6,12,13]. It is a matter of debate 
whether all cases cited completely fulfil the criteria 
of glucagon cell adenomatosis as defined by Henopp 
et al[1]. For example, the individual described by Yu 
et al[3] had not only raised serum glucagon levels but 
also pathologic values of pancreatic polypeptide. The 
patient reported by Balas et al[13] in 1988  had normal 
serum glucagon levels; however immunohistological 
findings in the resected pancreas were consistent with 
glucagon cell adenomatosis. In our patient, although 
the morphology of the resected pancreatic islets 
was within the broad range of findings reported in 
unaffected pancreata, we speculate that a cluster of 
hyperfunctioning cells might potentially be responsible 
for the development of hyperglucagonemia. Functional 
studies would be needed to confirm this theory. 
The majority of individuals had glucagon cell 
adenomatosis, but were asymptomatic with respect to 
evidence of the glucagonoma syndrome. The results of 
imaging ranged from no pathologic findings to diffuse 
pancreatic enlargement associated with multiple tumors 
of various sizes. Abdominal pain is present in most 
individuals as was the case in our patient (Table 3). 
While the case we present exhibited normal uptake on 
somatostatin receptor scintigraphy, diffusely increased 
uptake was reported on OctreoScan® in a patient with 
diffuse pancreatic enlargement and multiple tumors by 
Henopp et al[1]. In our patient the positive staining for 
chromogranin on FNA was thought to be suggestive of 
a neuroendocrine tumor. This might reflect the small 
number of cells obtained from the FNA, with a sampling 
error leading to a higher proportion of chromogranin 
positive cells (e.g., if FNA sampling comprised an islet). 
In comparison to two reported cases which had highly 
elevated serum glucagon levels, our patient had only 
slightly increased serum glucagon (Table 3). The lack of 
standardised serum glucagon reporting in the majority 
of cases and the small number of patients means it is 
difficult to tell if the levels in our patient were truly lower 
than average.
The majority of previously reported patients 
demonstrated numerous microadenomas expressing 
almost exclusively glucagon and/or glucagon cell 
hyperplasia. This observation prompted Henopp et al[1,14] 
to postulate that diffuse glucagon cell hyperplasia might 
represent a precursor from of glucagon cell neoplasia. 
In the case described by Yu et al[3], 60%­80% of the 
hyperplastic islet cells stained positive for glucagon but 
negative for insulin. A similar trend was noted by Henopp 
et al[1]. In our patient, the pancreatic morphology was 
unusual, nevertheless still within the wide range of 
physiological findings. Approximately 20% of the islet 
cells expressed glucagon while 80% expressed insulin. 
Based on this observation and only mildly increased 
serum glucagon, we hypothesize that the disease might 
have been diagnosed at a very early stage prior to 
evidence of hyperplasic transformation and development 
of overt morphological evidence of neoplasia/s. 
While a subcentimeter nodule at the pancreatic tail 
was evident on EUS and confirmed intraoperatively, 
standard histology showed regular findings. This 
scenario resembles a report by Martignoni et al[4] of 
hyperglucagonemia but no microadenomas. 
Both of the two previously reported patients for 
whom follow­up data was available showed increased 
serum glucagon levels after pancreatic resection in the 
presence of negative imaging results[1,3]. These findings 
underline the presumption of disease persistence. Our 
patient however, had normal serum glucagon levels at 
31 mo after surgery (10 pmol/L) (Table 1). Due to the 
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Figure 2  Genetic findings. A: Sequencing results showing a heterozygous 33 nucleotide deletion and 5 point mutations in exon 11 of the GCGR; B: Amino acid 
sequence showing K349_G359del, E362K, V368L, K381E, S389N in the GCGR. Alignments done using Clustal W multiple sequence alignments software [25]. 
Numbers indicate the position of the last residue shown along the GCGR cDNA/protein.
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genetic predisposition of the disease we cannot exclude 
the possibility that at some point in the future the 
disease may recur therefore our patient requires life­
long follow up. Any future increases in serum glucagon 
levels could potentially represent the emergence of 
alpha cell hyperfunction consistent with the concept of 
a residual genomic lesion representing a diffuse alpha 
cell abnormality in the remaining pancreatic islets.
The GCGR is a member of the class B G protein­
coupled receptor family, glucagon binding triggers 
downstream signalling, allowing glucagon to regulate 
blood glucose levels by stimulating glycogenolysis[15,16]. 
The knockout mouse for GCGR expresses high 
glucagon levels associated with pancreatic enlargement, 
glucagon cell adenomatosis and microglucagonomas 
or glucagonomas at 10­12 mo when compared to 
their heterozygous littermates[17,18]. Based on these 
observations, Yu et al[3,6] sequenced GCGR and the 
glucagon gene in their patient with hyperglucagonemia, 
alpha cell hyperplasia and microglucagonoma. They 
detected a homozygous c.256C>T (P86S) mutation 
in GCGR resulting in lower binding affinity of GCGR 
P86S to glucagon and hypothesized that this mutation 
was responsible for the alpha cell hyperplasia and 
hyperglucagonemia. They showed in vitro that the 
GCGR P86S localized to the plasma membrane but 
bound glucagon with less avidity than wild type 
GCGR; a greater glucagon concentration was thus 
needed to trigger downstream signalling via adenylate 
cyclase activation[6]. Neuroendocrine cells undergoing 
hyperplastic changes is particularly relevant for 
MEN1 conditions however they probably also occur in 
sporadic cases. Very recently Klöppel et al[14] identified 
3 further patients with germline GCGR mutations and 
glucagon cell adenomatosis unrelated to MEN1 or VHL 
syndromes. The genetic lesions present in the GCGR 
were not described, however a further 3 patients had 
glucagon cell adenomatosis in the absence of any 
GCGR mutation[14].
Our case represents the second case with genetic 
lesions described in the GCGR associated with 
hyperglucagonemia in the absence of the glucagonoma 
syndrome. The heterozygous K349_G359del and 
E362K, V368L, K381E, S389N mutations could 
potentially represent a loss of function mutation in 
the GCGR. Functional studies would be needed to 
show if these mutations might be the cause of the 
hyperglucagonemia observed in our patient. All 
mutations were in exon 11 towards the C terminal end 
of GCGR. The point mutations appear to represent 
rather conservative amino acid changes in terms of 
hydrophobicity. Lysine and glutamate have a positively 
and a negatively charged R group respectively and the 
serine to asparagine change represents an alteration 
from a hydroxyl R group to a carboxamide R group. Site 
directed mutagenesis studies have noted that D385 is 
relevant to the specificity of glucagon/GCGR binding[19]. 
Since this residue is close to the K381E mutation site 
and adjacent to the glucagon binding site, the alteration 
in R group may affect glucagon binding. However in the 
absence of high resolution crystal structure data for the 
human glucagon receptor (except for the extracellular N 
terminal domain) and site directed mutagenesis studies 
for these sites, the effects of these genetic changes 
cannot be directly inferred[15]. 
The K349_G359del falls within the 6th transmembrane 
domain of GCGR, therefore the 11 amino acid deletion 
could prevent GCGR from inserting into the plasma 
membrane. This would prevent GCGR binding to 
glucagon[20]. In structural studies where COS­1 cells 
were transfected with the rat glucagon receptor 
gene, truncation mutants lacking any of the different 
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Table 3  Hyperglucagonemia without the glucagonoma syndrome-review of the literature
Martignoni et  al [4] Henopp et  al [1] (patient 2) Yu et  al [3], Zhou et  al [6] Present case
Patient 54, M 43, F 60, F 36, F
Origin - - Persian Caucasian
Clinical symptoms Abdominal pain
Diarrhea1
Abdominal pain Abdominal pain
Constipation
Abdominal pain
Serum Glucagon (pmol/L) Elevated Elevated (25-fold)2 170113 66
Imaging Negative Positive Positive Negative (positive on EUS)
OctreoScan® Negative - Negative Negative
Localization No focal abnormality Tail Uncinate Tail
Pancreatic pathology α-cell hyperplasia
nesidioblastosis
α-cell hyperplasia, large cystic 
tumor and small solid tumors, 
multiple microadenomas
α-cell hyperplasia non-
functioning pancreatic NET
microglucagonoma
microadenoma
Normal pancreatic morphology on 
standard H and E staining
GCGR - - Homozygous
gDNA point mutation
Heterozygous gDNA deletion 5 
point mutations
Other Genes - Negative for MEN1/VHL 
gDNA mutations
- Negative for MEN1/VHL gDNA 
mutations
Relatives GCGR - - Brother
Negative
Daughter
Negative
1Mild diabetes was initially suspected but then found to be unlikely; 2The glucagon levels were only measured postoperatively; 3Glucagon levels converted 
to pmol/L from pg/mL. M: Male; F: Female; EUS: Endoscopic ultrasound; GCGR: Glucagon receptor.
transmembrane domains, were not localized to the 
plasma membrane suggesting that all 7 transmembrane 
domains are needed for correct membrane insertion[21]. 
The K349_G359del mutation is predicted by membrane 
topology prediction software to prevent the GCGR 
from properly inserting into the plasma membrane[22] 
(Figure 3). If this was the case, then the GCGR would 
be miss­localized preventing glucagon binding. This 
would however need to be confirmed by in vitro protein 
localization studies and assays to check glucagon binding 
efficiency in the presence of the deletion. In addition, 
since the mutation in the GCGR is heterozygous, there 
would still be a normal gene copy present which might 
allow sufficient glucagon signalling via the remaining 
receptors to give normal function. However, the clinical 
pathology evident in the presence of hyperglucagonemia 
seems to suggest that this may not be the case. 
The phenotype could potentially represent incomplete 
dominance leading to the modest elevation of serum 
glucagon in our patient. Alternatively, it is possible that 
this individual might have a second mutation in the other 
copy of the GCGR within some of the pancreatic alpha 
cells which could potentially be causing them to become 
hyperfunctional.
It has been previously suggested that incretin 
treatment is associated with the development of alpha 
cell hyperplasia since pancreata from autopsies of 
incretin treated persons exhibit alpha cell hyperplasia 
(and beta cell hyperplasia) and some had glucagon 
expressing microadenomas[23,24]. A possibility exists that 
as incretin usage increases, alpha cell hyperplasia may 
become more prevalent. 
In conclusion, we have identified a novel hete­
rozygous K349_G359 deletion and 4 missense mutations 
in the GCGR which appear to be associated with 
hyperglucagonemia without the glucagonoma syndrome. 
Physicians dealing with pancreatic disorders should be 
aware of this very unusual condition. Further study leading 
to a better understanding of this disease entity would 
be of benefit to patients.  The further usage of GCGR 
sequencing in such individuals should be undertaken 
to provide additional information on the breadth of the 
spectrum of mutational abnormalities associated with 
alpha cell transformation and excess glucagon production.
COMMENTS
Case characteristics
36 years old patient with a 10 year history of non-specific diffuse abdominal pain.
Clinical diagnosis
A sub-centimeter lobulated lesion was found at the inferior margin of the 
pancreatic tail, no further lesions were identified in the remaining pancreas after 
meticulous bimanual exploration and intraoperative ultrasound.
Differential diagnosis
Fine needle aspiration revealed cells focally expressing CgA. The features were 
suggestive but not diagnostic of a low grade neuroendocrine tumor.
Laboratory diagnosis
Serum glucagon was elevated to 66 pmol/L (normal: 0-50 pmol/L). Other gut 
hormones were within the normal range. 
Imaging diagnosis
Endoscopic ultrasound identified a 5.5 mm hypoechoic lesion with irregular 
margins in the pancreatic tail.
Pathological diagnosis
Histology (H and E) showed features of normal pancreatic tissue. Glucagon cell 
hyperplasia was initially considered based on glucagon immunohistochemistry. 
Further investigation revealed that the average islet size and the average 
number of glucagon positive cells per islet were increased in the patient, 
however still within the wide range observed in normal pancreatic tissue.
Treatment
At laparotomy, a sub-centimeter lobulated lesion was found at the inferior 
margin of the pancreatic tail and was enucleated.
Related reports
This is a very rare disease entity. Genetic lesions in the glucagon receptor 
(GCGR) have only been described in one individual in the literature in the 
context of glucagon cell adenomatosis with hyperglucagonemia but without 
glucagonoma syndrome. Several additional cases exhibiting the characteristics 
of glucagon cell adenomatosis with hyperglucagonemia but without 
glucagonoma syndrome have been published however their GCGR mutation 
status remains unknown.
Experiences and lessons
The authors have identified novel GCGR mutations which appear to be associated 
with hyperglucagonemia without the glucagonoma syndrome. Physicians dealing 
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Figure 3  Membrane topology prediction. The loss of 11 amino acids from the glucagon receptor (GCGR) 6th transmembrane domain is predicted to prevent the 
insertion of GCGR into the plasma membrane. A: Predicted normal GCGR membrane topology; B: Predicted K349_G359del GCGR membrane topology. Software 
used: MetaTM[22]; input amino acid sequence shown in Figure 2B. DAS: Distributed Annotation System.
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with pancreatic disorders should be aware of this very unusual condition.
Peer-review
This is an interesting case of an entity not described before. 
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